[1] KING E O. Studies on a group of previously unclassified bacteria associated with meningitis in infants[J]. Am J Clin Pathol, 1959, 31(3): 241-247.
[2] KIM K K, KIM M K, LIM J H, et al. Transfer of Chryseobacterium meningosepticum and Chryseobacterium miricola to Elizabethkingia gen. nov. as Elizabethkingia meningoseptica comb. nov. and Elizabethkingia miricola comb. nov[J]. Int J Syst Evol Microbiol, 2005, 55(Pt 3): 1287-1293.
[3] 冯孟文, 张梦怡, 周静. 伊丽莎白菌属感染流行病学及耐药性研究进展[J]. 中国感染控制杂志, 2024, 23(3): 391-396.
[4] WANG L, ZHANG X, LI D, et al. Molecular characteristics and antimicrobial susceptibility profiles of Elizabethkingia clinical isolates in Shanghai, China[J]. Infect Drug Resist, 2020, 13: 247-256.
[5] CHANG Y C, LO H H, HSIEH H, et al. Identification and epidemiological relatedness of clinical Elizabethkingia meningoseptical isolates from central Taiwan[J]. J Microbiol Immunol Infect, 2014, 47(4): 318-323.
[6] 孙桂芹, 李蒙, 王蕾, 等. 脑膜炎败血伊丽莎白金菌感染的临床分布及耐药性分析[J]. 中国微生态学杂志, 2014, 26(5): 540-543.
[7] LEE D H, PATEL R H, MEHRA I, et al. A case series of Elizabethkingia meningosepticum bacteremia in the cancer population[J]. Cureus, 2021, 13(10): e18627.
[8] 丁露, 鲁琼, 屈强, 等. 脑膜败血伊丽莎白菌医院感染的临床特征及抗感染治疗分析[J]. 中南药学, 2022, 20(3): 689-692.
[9] MA S, GONG Y, LUO X, et al. Emerging prevalence and clinical features of Elizabethkingia meningoseptica infection in southwest China: a 9-year retrospective study and systematic review[J]. Infect Drug Resist, 2023, 16: 531-543.
[10] HUNG P P, LIN Y H, LIN C F, et al. Chryseobacterium meningosepticum infection: antibiotic susceptibility and risk factors for mortality[J]. J Microbiol Immunol Infect, 2008, 41(2): 137-144.
[11] 俞容, 徐娇君, 金东芳, 等. 医院感染脑膜败血伊丽莎白菌的临床特点、产酶情况与耐药性分析[J]. 中国卫生检验杂志, 2020, 30(24): 2967-2970.
[12] JEAN S S, LEE W S, CHEN F L, et al. Elizabethkingia meningoseptica: an important emerging pathogen causing healthcare-associated infections[J]. J Hosp Infect, 2014, 86(4): 244-249.
[13] KUO S C, TAN M C, HUANG W C, et al. Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods[J]. J Antimicrob Chemother, 2021, 76(3): 653-658.
[14] 孙萍, 许雨乔, 夏文颖, 等. 2012—2016年脑膜脓毒性伊丽莎白金菌临床分布及药敏结果[J]. 中国感染与化疗杂志, 2018, 18(4): 421-423.
[15] 吴朝霞, 方寅飞. 重症患者继发脑膜败血伊丽莎白菌感染的临床病因与耐药性[J]. 中国微生态学杂志, 2016, 28(1): 72-75.
[16] SPENCER H K, SPITZNOGLE S L, BORJAN J, et al. An overview of the treatment of less common non-lactose-fermenting gram-negative bacteria[J]. Pharmacotherapy, 2020, 40(9): 936-951.
[17] CHAN J C, CHONG C Y, THOON K C, et al. Invasive paediatric Elizabethkingia meningoseptica infections are best treated with a combination of piperacillin/tazobactam and trimethoprim/sulfamethoxazole or fluoroquinolone[J]. J Med Microbiol, 2019, 68(8): 1167-1172.
[18] RATNER H. Flavobacterium meningosepticum[J]. Infect Control, 1984, 5(5): 237-239.
[19] 陶琪, 王彩莲. 下呼吸道感染脑膜败血伊丽莎白菌的临床分布及耐药性分析[J]. 中国乡村医药, 2016, 23(13): 41-42.
[20] MA S, GONG Y, LUO X, et al. Emerging prevalence and clinical features of Elizabethkingia meningoseptica infection in southwest China:a 9-year retrospective study and systematic review[J].Infect Drug Resist, 2023, 16:531-543. |
